Surotomycin
Also known as: CB-064, CB-315, MK-4261, Surotomycin
Source Surotomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Surotomycin is a semisynthetic cyclic lipopeptide antibiotic developed for oral treatment of Clostridioides difficile infection. It reached Phase 2 clinical trials but was not pursued further due to lack of efficacy.
Mechanism of Action
Binds to bacterial cell membrane and disrupts membrane potential, causing rapid bactericidal activity against Gram-positive organisms including Clostridioides difficile
Routes of Administration
Goals & Uses
- Prevention of CDI recurrenceAnti InfectiveModerate
- Clostridioides difficile infectionInfectionModerate
- Treatment of Clostridioides difficile infectionAntimicrobialModerate
Contraindications
- Known hypersensitivity to surotomycin or related lipopeptidesAllergyHigh
- Hypersensitivity to surotomycin or related lipodepsipeptidesAllergyHigh
Adverse Effects
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Diarrhea (non‑C. difficile)GastrointestinalCommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
- Abdominal painGastrointestinalCommonPain or discomfort in the abdomen
Drug Interactions
- HMG-CoA reductase inhibitors (statins)Low
- Concurrent use of other antibioticsModerate
Population Constraints
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trials conducted; not approved by EMA
- United StatesInvestigationalInvestigational New Drug (IND) filed; no FDA approval
- United KingdomInvestigationalNo MHRA approval; development discontinued
No regulatory approval; development discontinued after Phase 2 trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Surotomycin?
Surotomycin is a semisynthetic cyclic lipopeptide antibiotic developed for oral treatment of Clostridioides difficile infection. It reached Phase 2 clinical trials but was not pursued further due to lack of efficacy.
What is Surotomycin used for?
Surotomycin is educationally associated with: Prevention of CDI recurrence, Clostridioides difficile infection, Treatment of Clostridioides difficile infection. Educational only — not medical advice.
How is Surotomycin administered?
Recorded routes of administration: Oral.
What are the potential side effects of Surotomycin?
Reported adverse effects include: Headache, Nausea, Vomiting, Diarrhea (non‑C. difficile), Diarrhea, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Surotomycin?
Recorded contraindications: Known hypersensitivity to surotomycin or related lipopeptides, Hypersensitivity to surotomycin or related lipodepsipeptides. Consult a qualified clinician before use.